Understand the source comparison
Best Peptides for Memory: Research Applications Comparison
Dihexa HGF mimetic; c-Met receptor activation → synaptogenesis 0.1–2 mg/kg (subcutaneous or oral) Oral: 50–60%; Subcutaneous: ~100% 28 days at 2–8°C Highest potency-per-dose; oral administration viable; limited human safety data P21 CREB pathway activator; CBP
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dihexa
- HGF mimetic; c-Met receptor activation → synaptogenesis
- 0.1–2 mg/kg (subcutaneous or oral)
- Oral: 50–60%; Subcutaneous: ~100%
- 28 days at 2–8°C
- Highest potency-per-dose; oral administration viable; limited human safety data
- P21
- CREB pathway activator; CBP KIX domain mimetic
- 1–3 mg intranasal (rodent); ~10–30 mg human-equivalent
- Intranasal with rapid CNS delivery
- Strong preclinical memory encoding effects; nasal administration simplifies protocol
- Cerebrolysin
- Multi-target neurotrophic peptide mixture (BDNF, GDNF, NGF fragments)
- 10–60 mL IV over 20–30 days
- Intravenous only
- Pre-mixed; use within labeled shelf life
- Extensive clinical trial data; requires medical administration; broader neuroprotection
- Thymalin
- Thymic bioregulator; immune modulation reduces neuroinflammation
- 10–20 mg subcutaneous; 10-day cycles
- Subcutaneous
- Indirect cognitive benefit via inflammation reduction; best for aging/neuroinflammation models
- The choice between these compounds depends on research focus. Labs studying synaptic plasticity mechanisms gravitate toward Dihexa and P21 for their specificity and measurable effects on dendritic spine density and CREB phosphorylation. Researchers modeling neurodegenerative conditions or stroke recovery use Cerebrolysin for its multi-system neuroprotection and established clinical precedent. Thymalin fits immune-aging studies where chronic inflammation is the variable of interest.